Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
出版年份 2014 全文链接
标题
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
作者
关键词
Akt inhibitor MK-2206, Ezrin T567, AIF, Cell survival, Cell death, Akt isoforms, PI3K, XIAP, Survivin
出版物
BMC CANCER
Volume 14, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-03-02
DOI
10.1186/1471-2407-14-145
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cell survival and metastasis regulation by Akt signaling in colorectal cancer
- (2013) Ekta Agarwal et al. CELLULAR SIGNALLING
- A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle
- (2012) Yu-Chiang Lai et al. BIOCHEMICAL JOURNAL
- Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
- (2012) C Simioni et al. LEUKEMIA
- Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma
- (2011) Y. Chen et al. CANCER RESEARCH
- Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells
- (2011) Nicole Grabinski et al. CELLULAR SIGNALLING
- Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death
- (2011) Sanjib Chowdhury et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
- (2011) Ruixin Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
- (2011) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program
- (2011) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- Identification of a Novel TGFβ/PKA Signaling Transduceome in Mediating Control of Cell Survival and Metastasis in Colon Cancer
- (2011) Sanjib Chowdhury et al. PLoS One
- IAP Regulation of Metastasis
- (2010) Swarna Mehrotra et al. CANCER CELL
- HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways
- (2010) Hiromichi Nakabayashi et al. CANCER SCIENCE
- The Effects of Epidermal Growth Factor Receptor Activation and Attenuation of the TGFβ Pathway in an Orthotopic Model of Colon Cancer
- (2009) Melanie Ongchin et al. JOURNAL OF SURGICAL RESEARCH
- Current overview of the role of Akt in cancer studies via applied immunohistochemistry
- (2008) Viktor Shtilbans et al. Annals of Diagnostic Pathology
- Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
- (2008) X Yang et al. BRITISH JOURNAL OF CANCER
- Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells
- (2008) Qiong Li et al. CANCER LETTERS
- Heterogeneity of Receptor Function in Colon Carcinoma Cells Determined by Cross-talk between Type I Insulin-like Growth Factor Receptor and Epidermal Growth Factor Receptor
- (2008) Y. P. Hu et al. CANCER RESEARCH
- Transforming Growth Factor Induces Apoptosis through Repressing the Phosphoinositide 3-Kinase/AKT/Survivin Pathway in Colon Cancer Cells
- (2008) J. Wang et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now